Capnia Reports Fourth Quarter and Full Year 2014 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Capnia Reports Fourth Quarter and Full Year 2014 Financial Results

REDWOOD CITY, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- Capnia, Inc. (Nasdaq: CAPN ), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced financial results for the fourth quarter and twelve months ended December 31, 2014.

"Capnia completed several important milestones in 2014, including a successful initial public offering and the launch of CoSense®, the only device available for accurate assessment of end-tidal carbon monoxide (ETCO) in newborns," said Anish Bhatnagar, M.D., Chief Executive Officer of Capnia. "The commercial rollout of CoSense is proceeding in the U.S. We also continue to evaluate the potential of our therapeutic nasal CO 2 technology for the treatment of symptomatic allergic rhinitis, cluster headache and trigeminal neuralgia (TN). This is an exciting time for the Company, and we look forward to communicating our progress throughout 2015."

Fourth Quarter 2014 and Recent Highlights

  • Completion of Series B Warrant Transaction. In March 2015, Capnia completed a privately negotiated transaction with certain holders of Capnia's Series B warrants who agreed to exercise their Series B warrants to purchase an aggregate of 589,510 shares of Capnia's Common Stock at an exercise price of $6.50 per share, resulting in gross proceeds to the Company of approximately $3.8 million. In connection with this exercise of Series B warrants, Capnia issued to each investor who exercised Series B warrants, new Series C warrants exercisable at $6.25 per share for the same number of shares of Common Stock underlying the Series B warrants that were exercised. The cashless exercise feature that was contained in the Series B warrant that results in an increasing number of shares of Common Stock issuable without consideration as the price of the Common Stock decreases is not contained in the Series C warrants. Capnia intends to offer to all remaining holders of Series B warrants pursuant to a formal tender/registered exchange offer process, subject to certain limitations, the opportunity to exercise the Series B warrants held by them and receive Series C warrants on the same basis as in the private transaction.
     
  • Announced First U.S. Commercial Sales of CoSense. In February 2015, Capnia announced the first commercial sales of the Company's CoSense ETCO Monitors and single-use sampling sets to leading healthcare institutions.
     
  • Presented CoSense Data at the 2014 American Society of Hematology.   In December 2014, Capnia presented proof-of-concept data for the Company's CoSense ETCO Monitor in patients with sickle cell anemia (SCA) at the 2014 American Society of Hematology Annual Meeting and Exposition in San Francisco. The Company believes CoSense has potential applications in the monitoring of a range of diseases involving hemolysis and altered bilirubin metabolism, and data from this study supports the potential of CoSense as a screening tool for neonates at risk for SCA.
     
  • Applied for Orphan Drug Designation in the U.S. for the Treatment of Trigeminal Neuralgia.   In December 2014, Capnia submitted an application to the U.S. Food and Drug Administration (FDA) requesting Orphan Drug Designation for its nasal CO 2 technology for the treatment of TN. TN is a clinical condition characterized by debilitating pain in regions of the face innervated by one or more divisions of the trigeminal nerve.
     
  • Planned Partnership with Clinvest® to Develop Treatment for Cluster Headache.   In January 2015, Capnia announced the execution of a Memorandum of Understanding (MOU), whereby the Company and Clinvest®, a research organization dedicated to the advancement of medicine and health management through clinical research, will collaborate to develop a therapeutic product for the treatment of cluster headache using Capnia's proprietary nasal CO 2 technology. Under the terms of the MOU, Clinvest is expected to conduct an investigator-sponsored clinical trial evaluating Capnia's nasal CO 2 on up to 50 patients with episodic cluster headaches. Capnia will provide the investigational product and logistical support for the trial, as well as limited financial support.
     
  • Completion of Initial Public Offering. In November 2014, Capnia completed its IPO of 1,650,000 units, each unit consisting of one share of common stock, one Series A warrant (exercisable into one share of common stock) and one Series B warrant (exercisable into one share of common stock) resulting in aggregate net proceeds of approximately $8.0 million. Proceeds from the IPO will be used to fund the ongoing commercial launch of CoSense, and related costs, and for working capital, capital expenditures, and other corporate purposes.

Fourth Quarter 2014 Financial Results

No revenue was recognized in the three months ended December 31, 2014 or December 31, 2013.

Research and development expenses in the fourth quarter of 2014 were $0.6 million, compared to $0.4 million in the fourth quarter of 2013. The increase was primarily due to reimbursement of R&D expense of $0.3 million under the GSK license agreement in the fourth quarter of 2013. The GSK license agreement was terminated in the second quarter of 2014. Exclusive of this reimbursement R&D expenses were largely constant in both quarters.

Sales and marketing expenses in the fourth quarter of 2014 were $0.2 million. There were no sales and marketing expenses for the year ended December 31, 2013. The increase was primarily due to the addition of the Vice President of Sales in June 2014 and the commercial launch activities for CoSense initiated in October 2014.

General and administrative expenses in the fourth quarter of 2014 increased to $1.1 million, compared to $0.2 million in the fourth quarter of 2013. The increase was primarily due to an increase in consulting costs, employee related costs due to increased headcount and an increase in stock based compensation expense of $0.3 million in 2014 versus 2013.

Interest expense increased by $1.9 million in the fourth quarter of 2014 compared to the fourth quarter of 2013. This increase was primarily due to the write-off of the unamortized balance of the debt discount associated with the 2014 convertible notes as of November 18, 2014 (the IPO date).

Other expense in the fourth quarter of 2014 increased by $3.6 million compared to the fourth quarter of 2013. This increase was due to an increase of $5.8 million in the fair value of the Series B warrant liability from November 18, 2014 to December 31, 2014, and a net decrease of $2.2 million in the fair value of other stock warrants.

Net loss for the fourth quarter of 2014 was $7.9 million, or a loss of $2.23 per share, compared to a net loss of $1.0 million, or a loss of $1.82 per share, for the fourth quarter of 2013.

Cash, cash equivalents, and marketable securities at December 31, 2014 totaled $8.0 million. This compared to $1.3 million at December 31, 2013.

Full Year 2014 Financial Results

There was no revenue for the twelve months ended December 31, 2014, compared to $3.0 million for the twelve months ended December 31, 2013. The $3.0 million of revenue in the fiscal year ended December 31, 2013 represented the revenue from the license agreement with GSK.

Research and development expenses for the twelve months ended December 31, 2014 decreased 6% to $2.2 million, compared to $2.4 million for the same period in 2013. The decrease was primarily due to employee related costs due to lower headcount in 2014 versus 2013.

Sales and marketing expenses for the twelve months ended December 31, 2014 were $0.3 million. There were no sales and marketing expenses for the year ended December 31, 2013. The increase was primarily due to the addition of the Vice President of Sales in June 2014 and commercial launch activities for CoSense.

General and administrative expenses for the twelve months ended December 31, 2014 increased 82% to $2.7 million, compared to $1.5 million for the same period in 2013.  The increase was primarily due to an increase in consulting costs, employee related costs, including stock compensation expense of $0.3 million, due to increased executive headcount in 2014 versus 2013.

Interest expense increased by $1.3 million for the twelve months ended December 31, 2014 compared to the same period in 2013. This increase was primarily due to the write-off of the unamortized balance of the debt discount associated with the 2014 convertible notes as of November 18, 2014 (the IPO date).

Other expense for the twelve months ended December 31, 2014 increased by $4.6 million compared to the same period in 2013. This increase was due to an increase of $5.8 million in the fair value of the Series B warrant liability from November 18, 2014 to December 31, 2014, offset by a net decrease of $1.2 million in the fair value of other stock warrants.

Net loss for the twelve months ended December 31, 2014 was $13.9 million, or a loss of $10.92 per share, compared with a net loss of $3.7 million, or a loss of $5.10 per share, for the same period in 2013.

About Capnia

Capnia, Inc. develops and commercializes novel products based on its proprietary technologies for precision metering of gas flow. Capnia's lead product is CoSense®, which aids in the detection of hemolysis, a dangerous condition in which red blood cells degrade rapidly. CoSense, based on the Sensalyze™ Technology Platform, is a portable, non-invasive device that rapidly and accurately measures carbon monoxide in exhaled breath. CoSense has 510(k) clearance from the FDA and has also received CE Mark certification for sale in the European Union. Capnia's proprietary therapeutic technology, currently under development, uses nasal, non-inhaled CO 2 and is being evaluated to treat the symptoms of allergies, as well as the trigeminally mediated pain conditions such as cluster headache, TN and migraine.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned product development and clinical trials and the ability to receive Orphan Drug Designation approval from the FDA.

We may use terms such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Additional factors that could materially affect actual results can be found in Capnia's Form 10-Q filed with the Securities and Exchange Commission on December 18, 2014, including under the caption titled "Risk Factors." Capnia expressly disclaims any intent or obligation to update these forward looking statements, except as required by law.

 
 
Capnia, Inc.
Condensed Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
         
  Three Months Ended Fiscal Year Ended
  December 31, December 31,
  2014 2013 2014 2013
         
Revenue  --   --   --   $ 3,000
Expenses        
Research and Development  608  360  2,242  2,380
Sales and Marketing  157  --   253  -- 
General and Administrative  1,080  199  2,665  1,467
         
Total expenses  1,845  559  5,160  3,847
         
Operating income (loss)  (1,845)  (559)  (5,160)  (847)
         
Interest and other income (expense)        
Interest income  --   --   1  2
Interest expense  (2,319)  (389)  (4,130)  (2,860)
Other expense  (3,690)  (26)  (4,586)  (2)
         
Net loss and comprehensive loss  $ (7,854)  $ (974)  $ (13,875)  $ (3,707)
         
Basic and diluted net loss per common share  $ (2.23)  $ (1.82)  $ (10.92)  $ (5.10)
         
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share  3,516,886  535,685  1,270,033  535,648
 
 
Capnia, Inc.
Condensed Balance Sheets
(In thousands)
     
  As of December 31, As of December 31,
  2014 2013
Assets    
Current Assets    
Cash & Cash Equivalents  $ 7,957  $ 1,269
Restricted Cash  20  20
Accounts Receivable  --   150
Inventory  109  -- 
Prepaid expenses and other current assets  252  85
 Total Current Assets  8,338  1,524
Long-term Assets    
Property & Equipment, net  58  63
 Total Assets  $ 8,396  $ 1,587
     
Liabilities, convertible preferred stock and stockholders' deficit    
Current Liabilities    
Accounts Payable  $ 987  $ 58
Accrued expenses  201  129
Line of Credit  102  -- 
Convertible promissory notes and accrued interest  --   13,992
Total Current Liabilities  1,290  14,179
Long-Term Liabilities    
Series B Warrant Liability  17,439  -- 
Convertible preferred stock warrant liability  --   1,464
Commitments and Contingencies    
Convertible Preferred Stock    
Series A convertible preferred stock, $0.001 par value, 40,000 shares authorized, 0 and 31,250 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively; (aggregate liquidation preference of $1,500)  --   1,500
Series B convertible preferred stock, $0.001 par value, 320,000 shares authorized, 0 and 119,140 shares issued and outstanding at December 31, 2014 and December 31, 2013 respectively; (aggregate liquidation preference of $6,863)  --   6,863
Series C convertible preferred stock, $0.001 par value, 1,500,000 shares authorized, 0 and 715,039 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively; (aggregate liquidation preference of $15,445)  --   15,445
Stockholder's deficit    
Common stock, $0.001 par value, 100,000,000 shares authorized at December 31, 2014 and 10,000,000 shares authorized at December 31, 2013; 6,769,106 and 535,685 shares issued and outstanding at December 31, 2014 and December 31, 2013  7  1
Additional paid-in-capital  60,635  19,235
Accumulated deficit  (70,975)  (57,100)
Total stockholders' deficit  (10,333)  (37,864)
 Total liabilities and stockholders' deficit  $ 8,396  $ 1,587

Capnia Contact: David O'Toole Chief Financial Officer Capnia, Inc. (650) 353-5146 Investor Relations Contact: Michelle Carroll/Susie Kim Argot Partners (212) 600-1902

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 58

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 183

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 112

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 109

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 11

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 113

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 296

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading

Top 5 Most Recently Viewed Articles

Class Action Alert: KBR, Inc. Investors Should Take Note

Updated Category News Views 351

Class Action Alert for KBR, Inc. Investors Attention to all stakeholders of KBR, Inc. (NYSE: KBR): there has been significant news affecting your investments. A class action lawsuit is underway, compelling shareholders to reflect on the recent allegations against the company. Amidst claims of misleading communications concerning a crucial contract, KBR's stock has been...

Continue Reading
PyroGenesis Reports Q3 2025 Performance and Future Outlook

Updated Category News Views 192

Financial Insights from PyroGenesis' Q3 2025 PyroGenesis Inc. (TSX:PYR), a frontrunner in plasma-based technologies for heavy industry and defense, has unveiled its financial and operational results for the third quarter of 2025. This report highlights a revenue of $3.25 million, which reflects an 18.7% decline from the same period last year. This downturn is attributed...

Continue Reading
Metacon Reports Remarkable Revenue Growth in Q1 2025

Updated Category News Views 443

Metacon Achieves Significant Financial Milestones in Q1 2025 The first quarter of 2025 has marked an exciting chapter for Metacon, showcasing remarkable progress both financially and operationally. During this period, the company realized net sales of SEK 50 million, a substantial increase compared to SEK 8.3 million in the same quarter last year. This remarkable growth...

Continue Reading
Revolutionizing Workplace Productivity with Humanyze Insights

Updated Category News Views 106

Transforming the Workforce with AI-Driven Insights Humanyze, a pioneer in workforce analytics, recently unveiled Humanyze Insights, a cutting-edge platform specifically designed to enhance workforce productivity, drive profitability, and inspire sustainable growth for organizations. This AI-powered solution signifies a notable evolution from Humanyze’s previous...

Continue Reading
SKE Invigorates IRONWORKS London's Music Vibe With E-Cigs

Updated Category News Views 646

Bringing SKE's Flair to London's Music Scene Well, folks, hold onto your hats—SKE's thrown its weight behind IRONWORKS London, extending its reach deeper into the UK's electronic music scene. This ain't just another gig; we're talking about the second time SKE is flexing its sponsorship muscles in the UK music arena, officially angling for the vape category spotlight....

Continue Reading